Diagnostics industry companies, patient groups, [BB1]and trade associations are speaking up in the wake of last week’s news that US Food and Drug Administration user fee reauthorization legislation – which Congress must pass soon to maintain agency operations – might not include long-discussed diagnostic regulatory reforms.
The VALID (Verifying Accurate Leading-edge IVCT Development) Act, which would allow the FDA to regulate in vitro diagnostics, including lab-developed tests (LDTs), had been bundled into the Senate’s user fee...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?